EMA's Orphan Drug Program Update Looking At Similarity Standard
This article was originally published in The Pink Sheet Daily
EMA can't approve a similar product during an orphan drug's 10-year exclusivity period, but some criteria for that determination have not been officially defined.
You may also be interested in...
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.